Table 3.
Duration of follow-up (in years) | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|
|
||||||||||
Age group (in years) | 1 | 2 | 3 | 4 | 5 | |||||
|
|
|
|
|
||||||
Male | Female | Male | Female | Male | Female | Male | Female | Male | Female | |
0 | 0.89 | 0.87 | 0.79 | 0.80 | 0.71 | 0.71 | 0.66 | 0.65 | 0.62 | 0.60 |
1–4 | 0.93 | 0.91 | 0.86 | 0.83 | 0.78 | 0.78 | 0.70 | 0.70 | 0.66 | 0.66 |
5–9 | 0.92 | 0.92 | 0.84 | 0.82 | 0.81 | 0.78 | 0.77 | 0.72 | 0.73 | 0.68 |
10–14 | 0.90 | 0.89 | 0.85 | 0.81 | 0.79 | 0.73 | 0.74 | 0.69 | 0.72 | 0.65 |
15–19 | 0.87 | 0.87 | 0.80 | 0.78 | 0.72 | 0.72 | 0.64 | 0.64 | 0.62 | 0.58 |
20–24 | 0.87 | 0.83 | 0.77 | 0.75 | 0.69 | 0.69 | 0.66 | 0.66 | 0.59 | 0.61 |
25–29 | 0.86 | 0.89 | 0.77 | 0.79 | 0.69 | 0.67 | 0.60 | 0.54 | 0.56 | 0.52 |
30–44 | 0.87 | 0.90 | 0.76 | 0.81 | 0.69 | 0.76 | 0.64 | 0.71 | 0.62 | 0.67 |
45+ | 0.90 | 0.92 | 0.85 | 0.87 | 0.79 | 0.82 | 0.74 | 0.77 | 0.70 | 0.74 |